X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2014) 2014
Publication (221) 221
Newsletter (49) 49
Book Review (20) 20
Magazine Article (14) 14
Newspaper Article (13) 13
Book Chapter (8) 8
Dissertation (7) 7
Conference Proceeding (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1388) 1388
nelfinavir (1209) 1209
hiv infections - drug therapy (804) 804
female (633) 633
male (608) 608
adult (505) 505
infectious diseases (493) 493
hiv protease inhibitors - therapeutic use (451) 451
pharmacology & pharmacy (448) 448
nelfinavir - therapeutic use (441) 441
protease inhibitors (424) 424
index medicus (401) 401
hiv (397) 397
ritonavir (372) 372
drug therapy, combination (364) 364
anti-hiv agents - therapeutic use (355) 355
indinavir (316) 316
nelfinavir - pharmacology (304) 304
antiretroviral therapy (300) 300
immunology (294) 294
viral load (279) 279
virology (278) 278
antiviral agents (277) 277
hiv protease inhibitors - pharmacology (277) 277
middle aged (266) 266
saquinavir (265) 265
hiv infections - virology (254) 254
pharmacokinetics (232) 232
nelfinavir - administration & dosage (215) 215
hiv-1 - drug effects (210) 210
cd4 lymphocyte count (203) 203
hiv protease inhibitors - pharmacokinetics (203) 203
reverse transcriptase inhibitors - therapeutic use (202) 202
animals (201) 201
lopinavir (200) 200
hiv protease inhibitors - administration & dosage (194) 194
hiv protease inhibitors - adverse effects (187) 187
nelfinavir - pharmacokinetics (186) 186
hiv-1 - genetics (180) 180
nelfinavir - adverse effects (180) 180
antiretroviral therapy, highly active (172) 172
treatment outcome (170) 170
ritonavir - therapeutic use (167) 167
human-immunodeficiency-virus (166) 166
aids (163) 163
hiv-1 (162) 162
drug therapy (158) 158
therapy (158) 158
efavirenz (157) 157
infection (156) 156
proteases (156) 156
child (155) 155
drug interactions (152) 152
adolescent (151) 151
highly active antiretroviral therapy (151) 151
hiv infection (150) 150
hiv protease inhibitors - blood (148) 148
microbiology (146) 146
zidovudine (145) 145
amprenavir (143) 143
research (143) 143
anti-hiv agents - administration & dosage (141) 141
nevirapine (141) 141
rna, viral - blood (137) 137
lamivudine (131) 131
lamivudine - therapeutic use (131) 131
protease inhibitor (127) 127
indinavir - therapeutic use (123) 123
anti-hiv agents (122) 122
pregnancy (116) 116
resistance (114) 114
child, preschool (113) 113
nelfinavir - blood (113) 113
anti-hiv agents - adverse effects (112) 112
oncology (112) 112
hiv infections - immunology (110) 110
mutation (110) 110
in-vitro (108) 108
health aspects (107) 107
drug administration schedule (106) 106
hiv infections - blood (106) 106
prospective studies (104) 104
ritonavir - pharmacology (102) 102
saquinavir - therapeutic use (100) 100
apoptosis (99) 99
cancer (99) 99
children (99) 99
active antiretroviral therapy (98) 98
ritonavir - administration & dosage (98) 98
mice (97) 97
virus diseases (97) 97
anti-hiv agents - pharmacokinetics (95) 95
hiv protease inhibitors (95) 95
time factors (95) 95
aged (94) 94
analysis (94) 94
hiv protease - genetics (94) 94
zidovudine - therapeutic use (94) 94
dose-response relationship, drug (91) 91
hiv-infection (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2042) 2042
French (16) 16
Spanish (16) 16
German (12) 12
Portuguese (6) 6
Japanese (3) 3
Chinese (2) 2
Dutch (2) 2
Italian (2) 2
Russian (2) 2
Polish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Pharmaceutics, ISSN 0378-5173, 03/2016, Volume 501, Issue 1-2, pp. 311 - 325
Poor aqueous solubility and moderate permeability of Nelfinavir mesylate (NFM) leads to high variability in absorption after oral administration. To improve... 
Oral bioavailability | Food effect | Dissolution | Apparent permeability | Self microemulsifying drug delivery system | BOX-BEHNKEN DESIGN | TOPICAL APPLICATION | ENHANCED BIOAVAILABILITY | VIVO EVALUATION | SOLUBLE WEAK BASES | LONG-CHAIN | IN-VITRO | DESIRABILITY FUNCTION | CHAIN TRIGLYCERIDES | PHARMACOLOGY & PHARMACY | Nelfinavir - chemistry | Emulsions | Polysorbates - chemistry | Intestinal Absorption - drug effects | Biological Availability | Male | Drug Delivery Systems | HIV Protease Inhibitors - pharmacokinetics | Linoleic Acids - administration & dosage | Ethylene Glycols - chemistry | Polysorbates - administration & dosage | Fasting - metabolism | HIV Protease Inhibitors - blood | Rabbits | Permeability - drug effects | Food-Drug Interactions | Solubility | Rats | HIV Protease Inhibitors - chemistry | HIV Protease Inhibitors - administration & dosage | Chemistry, Pharmaceutical | Gastrointestinal Tract - metabolism | Nelfinavir - blood | Animals | Surface-Active Agents - administration & dosage | Surface-Active Agents - chemistry | Ethylene Glycols - administration & dosage | Nelfinavir - pharmacokinetics | Nelfinavir - administration & dosage | Linoleic Acids - chemistry | Drugs | Antiviral agents | Drug delivery systems | Nelfinavir | Vehicles | Thermodynamics | Surface active agents | Analysis | Permeability
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2012, Volume 70, Issue 6, pp. 791 - 799
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2016, Volume 113, Issue 32, pp. E4671 - E4680
Journal Article
EMBO reports, ISSN 1469-221X, 10/2016, Volume 17, Issue 10, pp. 1471 - 1484
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 25, pp. 2368 - 2379
In this randomized trial involving neonates whose HIV-infected mothers did not receive antenatal antiretroviral therapy (ART), combination ART significantly... 
VIRAL LOAD | ZIDOVUDINE TREATMENT | MEDICINE, GENERAL & INTERNAL | PERINATAL TRANSMISSION | POSTEXPOSURE PROPHYLAXIS | RESISTANCE | RANDOMIZED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | TO-CHILD TRANSMISSION | MATERNAL-INFANT TRANSMISSION | NEVIRAPINE | HIV-1 | HIV Infections - prevention & control | Humans | Drug Resistance, Viral | Male | Nevirapine - therapeutic use | Postpartum Period | Pregnancy Complications, Infectious | Nevirapine - adverse effects | Lamivudine - adverse effects | Drug Therapy, Combination - adverse effects | Lamivudine - therapeutic use | Female | HIV Infections - mortality | HIV Infections - transmission | Infant, Newborn | Nelfinavir - therapeutic use | Anti-Retroviral Agents - therapeutic use | Zidovudine - adverse effects | Infant Formula | Anti-Retroviral Agents - adverse effects | Kaplan-Meier Estimate | Nelfinavir - adverse effects | Pregnancy | Zidovudine - therapeutic use | Infectious Disease Transmission, Vertical - prevention & control | Drugs | Infants (Newborn) | Dose-response relationship (Biochemistry) | Control | Disease transmission | Product/Service Evaluations | Dosage and administration | Drug therapy | HIV infection | Health aspects | Zidovudine | Neonates | Antiretroviral drugs | Breastfeeding & lactation | Nevirapine | Toxicity | Prophylaxis | Lamivudine | Infants | Birth | Multivariate analysis | Antiretroviral therapy | Postpartum | Human immunodeficiency virus--HIV | Nelfinavir | Birth weight | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article